Immunoassays Compared to Improve Diagnosis of Chagas Disease
By LabMedica International staff writers Posted on 26 Oct 2019 |
Image: Indirect hemagglutination test for the detection of antibodies against Trypanosoma cruzi (Photo courtesy of Wiener lab. Group).
Chagas disease (CD), caused by the protozoan Trypanosoma cruzi, is a vector-borne infection of significant public health concern in Latin America, where nearly six million people are infected and 70 million are at risk of infection.
Up to 99% of CD cases in the Americas and more than 90% in Europe are undiagnosed. A key barrier is the complexity of the diagnostic process, which is hampered by the lack of a gold standard, availability of multiple types of assays with varying sensitivity and specificity, and the sheer difficulty of detecting the parasite in the chronic phase of the disease.
Scientists associated the Colombian National Institute of Health (Bogota, Colombia) used a panel of 501 serum samples obtained from whole blood and the samples reflected a broad spectrum of CD patients in Colombia. Patients ranged in age from 1 to 81, but only seven were under 18 years old. Mean patient age was 39.3 years and was younger in blood donors (22.3) than patients tested in public health laboratories (49.4).
Samples were characterized as positive (n = 256) or negative (n = 245) using standard procedures based on four serological assays: an in-house enzyme-linked immunosorbent assay (ELISA), optic density ≥ 0.300; an in-house immunofluorescence assay (IFA), dilution ≥ 1:32; an indirect hemagglutination; and immunoblots of trypomastigote excreted-secreted antigens.
The scientists assessed seven commercially available assays and found that five of seven assays exhibited sensitivity >98% while six showed specificity >97%. A total antigen ELISA paired with a recombinant assay provided similar performance to the current diagnostic process. Six of six assays tested proved capable of detecting different Trypanosoma cruzi genetic lineages. Of the 501 samples, 85.2% were correctly classified by all seven immunoassays; 222/256 positive samples (86.7%) and 202/245 (83.7%) negative samples.
The authors concluded that their study demonstrated the utility of systematically evaluating T. cruzi assays, using WHO standards, to validate national guidelines for CD diagnosis, strengthen quality control of diagnostic tools, and promote international standardization. A simplified testing process with two commercial assays could perform comparably to the previous process, reducing cost and accessibility barriers and facilitating national scale-up. The study was published in the October 2019 issue of the International Journal of Infectious Diseases.
Related Links:
Colombian National Institute of Health
Up to 99% of CD cases in the Americas and more than 90% in Europe are undiagnosed. A key barrier is the complexity of the diagnostic process, which is hampered by the lack of a gold standard, availability of multiple types of assays with varying sensitivity and specificity, and the sheer difficulty of detecting the parasite in the chronic phase of the disease.
Scientists associated the Colombian National Institute of Health (Bogota, Colombia) used a panel of 501 serum samples obtained from whole blood and the samples reflected a broad spectrum of CD patients in Colombia. Patients ranged in age from 1 to 81, but only seven were under 18 years old. Mean patient age was 39.3 years and was younger in blood donors (22.3) than patients tested in public health laboratories (49.4).
Samples were characterized as positive (n = 256) or negative (n = 245) using standard procedures based on four serological assays: an in-house enzyme-linked immunosorbent assay (ELISA), optic density ≥ 0.300; an in-house immunofluorescence assay (IFA), dilution ≥ 1:32; an indirect hemagglutination; and immunoblots of trypomastigote excreted-secreted antigens.
The scientists assessed seven commercially available assays and found that five of seven assays exhibited sensitivity >98% while six showed specificity >97%. A total antigen ELISA paired with a recombinant assay provided similar performance to the current diagnostic process. Six of six assays tested proved capable of detecting different Trypanosoma cruzi genetic lineages. Of the 501 samples, 85.2% were correctly classified by all seven immunoassays; 222/256 positive samples (86.7%) and 202/245 (83.7%) negative samples.
The authors concluded that their study demonstrated the utility of systematically evaluating T. cruzi assays, using WHO standards, to validate national guidelines for CD diagnosis, strengthen quality control of diagnostic tools, and promote international standardization. A simplified testing process with two commercial assays could perform comparably to the previous process, reducing cost and accessibility barriers and facilitating national scale-up. The study was published in the October 2019 issue of the International Journal of Infectious Diseases.
Related Links:
Colombian National Institute of Health
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms